donafenib
Trade name: Zepsun
Small moleculeexperimental
Clinical trial activity
49 trials · 26 clinical orgs · 0 marketing orgs
Phase 1
15
Phase 2
34
Phase 3
4
Phase 4
4
Earliest trial started Mar 1, 2014 (NCT02489916)
Timeline
Indications
Approved for
Studied for
- Antimetabolites · Phase 2
- Antineoplastic Agents · Phase 2
- Biliary Tract Neoplasms · Phase 2
- Carcinoma · Phase 2
- Carcinoma, Hepatocellular · Phase 4
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Cholangiocarcinoma · Phase 2
- Colorectal Neoplasms · Phase 3
- Digestive System Neoplasms · Phase 2
- Drug-Related Side Effects and Adverse Reactions · Phase 4
- Drugs, Investigational · Phase 2
- Drug Therapy · Phase 2
- Esophageal Neoplasms · Phase 1/Phase 2
- Fluorouracil · Phase 2
- Healthy Volunteers · Phase 1
- Intestinal Neoplasms · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 1
- Liver Neoplasms · Phase 2
- Nasopharyngeal Carcinoma · Phase 1
- Neoplasms · Phase 4
- Oxaliplatin · Phase 2
- Pancreatic Neoplasms · Phase 2
- Stomach Neoplasms · Phase 1/Phase 2
- Survival · Phase 2
- Thyroid Neoplasms · Phase 3
- Uterine Cervical Neoplasms · Phase 2
Mechanism of action
- Platelet-derived growth factor receptorANTAGONIST
Platelet-derived growth factor receptor antagonist
Vascular endothelial growth factor receptor antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cm4307
- donafenib
- donafenib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07157306 | Phase 2 | Sep 10, 2025 | Tianjin Medical University |
| NCT06812039 | Phase 2 | Jan 1, 2025 | Fudan University |
| NCT06685289 | Phase 4 | Nov 15, 2024 | Nanjing Medical University |
| NCT06646198 | Phase 2 | Oct 8, 2024 | Sun Yat-Sen University |
| NCT06609876 | N/A | Oct 1, 2024 | People's Liberation Army of China, Sun Yat-Sen University |
| NCT06581315 | N/A | Aug 28, 2024 | Sun Yat-Sen University |
| NCT06496815 | Phase 4 | Aug 1, 2024 | Huazhong University of Science and Technology |
| NCT06512467 | Phase 2 | Jul 30, 2024 | Tianjin Medical University |
| NCT06787911 | Phase 2 | Jul 24, 2024 | Fudan University |
| NCT06498622 | Phase 2 | Jul 20, 2024 | Anhui Medical University |
| NCT06239298 | Phase 1/Phase 2 (Phase 2) | May 10, 2024 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| NCT06233994 | N/A | Jan 31, 2024 | Changsha Taihe Hospital |
| NCT06244225 | Phase 2 | Jan 1, 2024 | Huazhong University of Science and Technology |
| NCT05673824 | Phase 4 | Feb 7, 2023 | Fudan University, LinkDoc Technology (Beijing) Co. Ltd. |
| NCT05545124 | Phase 2 | Nov 30, 2022 | Henan Medical University |
| NCT05668884 | Phase 2 | Oct 18, 2022 | Fudan University |
| NCT05576909 | Phase 2 | Oct 15, 2022 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd, Tsinghua University |
| NCT05493332 | Phase 2 | Sep 30, 2022 | Sun Yat-Sen University |
| NCT05507632 | Phase 2 | Aug 15, 2022 | Southern Medical University |
| NCT05348811 | Phase 2 | May 1, 2022 | Southeast University |
Showing 20 of 49 trials
Page 1 / 3
Organizations
Research & Development (26)
26 organizations
Page 1 / 2